Abstract: The present invention provides an oil-in-water cosmetic excellent in emulsion stability. The oil-in-water cosmetic includes (a) oil-droplet particles consisting of an oil component to be emulsified; (b) vesicle particles for stabilizing the oil-droplet particles; and (c) an aqueous phase containing water and a monohydric aliphatic alcohol having 1 to 4 carbon atoms. It is preferred that the vesicle particles are formed with an amphiphilic substance which spontaneously forms vesicle particles, and that they are localized on surfaces of the oil-droplet particles. It is preferred that the amphiphilic substance be a polyoxyethylene hydrogenated castor oil derivative represented by the following formula (I), wherein E=L+M+N+X+Y+Z, and that said E which represents the average addition mole number of ethylene oxide is 10 to 20.

Abstract: A polymeric biocidal salt is prepared from two components. The first component comprises a biocidal anionic or cationic monomeric, dendrimeric or polymeric ion. The second component comprises a dendrimeric or polymeric anion or cation having insignificant biocidal activity and a number average molecular weight of at least about 500. The second component will be cationic in nature when the first component is anionic in nature and anionic in nature when the first component is cationic in nature. The salt is further characterized as partially dissolving when exposed to an aqueous medium, thereby: (a) releasing sufficient biocidal ion to exceed the MIC or MBIC of a target bacteria sought to be controlled; and (b) leaving a reservoir of undissolved salt capable of being further dissolved and releasing additional biocidal ion as the biocidal ion is consumed or is otherwise removed from the environment encompassing the target bacteria.

Abstract: An antimicrobial composition comprises an anionic drug and an amine polymer comprising a first repeat unit of formula (2): wherein a? is an integer equal to 1 or 2, b? is an integer equal to 1 or 2, and each R? is an independent monovalent radical selected from the group consisting of hydrogen, methyl, ethyl, and combinations thereof. G? is a divalent linking group selected from the group consisting of a single bond and groups comprising at least one carbon. X? is a negatively charged counterion. The drug and the amine polymer are bound by noncovalent interactions.

Abstract: This invention pertains to method for imparting a durable antimicrobial activity to substrates, particularly textiles. An acetate-free metal and peroxide antimicrobial treatment formulation is prepared from a metal derivative, hydrogen peroxide and a source of hydroxide ion. The substrate is treated with the composition and dried to afford the treated substrate with antimicrobial activity. Zinc salts, ions, or complexes are preferred.

Abstract: The present invention relates compositions for delivering therapeutic agents from a medical device including an expandable and collapsible structure and methods employing them. A lipid coating including one or more fatty acids increases the amount of therapeutic agent released from the device at the delivery site. The therapeutic agent can be in a matrix including a hydrophilic polymer or an amphiphilic polymer. Release and adhesion coatings can also facilitate delivery of therapeutic agent.

Abstract: Absorbable, essentially non-absorbable, and non-absorbable crystalline, amphiphilic, block/graft copolymeric compositions exhibit an inherent viscosity of at least 0.5 dL/g, a heat of fusion of at least 10 J/g and undergo swelling in the biological environment due to a water up-take of at least 10 percent of original dry mass. These compositions are designed for use in swellable surgical sutures, coatings of medical devices, and carriers for the delivery of bioactive agents.

Abstract: The invention relates to a stent with in particular a coated basic body made of an implant material the use of lithium salts as a coating material or a component of an implant material for stents and the use of lithium salts in a method for restenosis prevention. The inventive stent having a basic body made of an implant material is characterized in that (i) the basic body has a coating which comprises or consists of a lithium salt, and/or (ii) the implant material is biocorrodible and the basic body contains a lithium salt.

Abstract: Provided are medical devices for implantation in patients having suffered the loss of or damage to at least part of their esophagus. The medical device connects the esophagus or remaining part thereof with the stomach to form a gastro-esophageal junction that promotes healing and encourages new host tissue growth while distributing the load and decreasing tension at the anastomotic site. The medical device comprises extracellular matrix shaped into a conformation that more closely approximates the geometry of the native gastro-esophageal junction than does direct attachment of the stomach to the shortened esophagus. Molds useful in manufacturing the medical device and methods of use of the device are also described herein.

Abstract: Bioabsorbable substrates having antimicrobial metal ion coatings that are well suited for implantation in to a subject's body to treat and/or prevent infection. In particular, described herein are flexible bioabsorbable filaments that are coated with an anodic metal (e.g., silver and/or zinc and/or copper) that is co-deposited with a cathodic metal (e.g., palladium, platinum, gold, molybdenum, titanium, iridium, osmium, niobium or rhenium) on the filament so that the anodic metal is galvanically released as antimicrobial ions when the apparatus is inserted into a subject's body. The anodic metal may be at least about 30 percent by volume of the coating.

Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Abstract: Methods for treating and preventing otitis externa with a course of treatment consisting of as little as a single dose are provided. The methods are practiced by topical administration of compositions having a lipid carrier, such as liposomes and non-vesicular lipids, to the outer ear canal. Such compositions lack viscocity-enhancing celluloses or adhesives, and are preferably not in the form of a gel. Active agents useful for treating pain, inflammation, fungal or parasitic infestation and/or infections in the outer ear are co-administered in or with the composition.

Abstract: The application relates to topical formulations comprising a phase II enzyme inducer precursor and an activating agent. Methods for producing and using the topical formulations are also provided.

Abstract: A compound sea cucumber product, preparation method thereof and dosage forms thereof are disclosed. A fresh sea cucumber is cut open, the viscus thereof is taken out, and they are well-cleaned respectively and put into an airtight container; at 70˜130° C., gelatinate for 1 min˜20 hours; thereafter freeze-dry till the water content is less than 10 wt %; apply coarse crushing till the fineness reaches 10˜300 mesh; then apply ultra-micro crushing by means of an airflow crusher until the fineness reaches 100˜3000 mesh; lastly apply nanometer crushing by means of high-energy ball grinding mill till the fineness reaches 10˜1000 nm. The nanometer sea cucumber extract is mixed with panax pseudo-ginseng saponins extract at the proportion of 99˜80 wt %:1˜20 wt %.

Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.

Abstract: A process for advantageously producing tablets having an improved release property and an excellent stability to change with time is provided. The process is for producing tablets containing a morphinan compound represented by the Formula (I) below or pharmaceutically acceptable acid addition salt thereof and an acidic substance such as fumaric acid, maleic acid or adipic acid, and characterized in that the morphinan compound or a pharmaceutically acceptable acid addition salt thereof is granulated by wet granulation together with (an) excipient(s) prior to adding the acidic substance thereto.

Abstract: The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans.

Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.

Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent.

Abstract: Oral insulin formulations and processes for preparing oral insulin formulations are provided.

Abstract: This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material.

Abstract: A method for preparing a gabapentin granulate comprising melt granulating gabapentin with polyethylene glycol having a melting point comprised between 50 and 80° C.

Abstract: The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles.

Abstract: The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.

Abstract: A production method is provided for obtaining a biologically ingestible material having an intended diameter with low energy as compared with conventional methods. The method includes mixing a fluid to be processed in a dispersed phase containing a pharmacologically active substance and a fluid to be processed in a continuous phase including at least a disperse solvent, while each of the fluids is retained in an independent state, in a thin film fluid formed between two processing surfaces arranged to be opposite to each other to be able to approach to and separate from each other, at least one of which rotates relative to the other, through independent pathways corresponding to the respective phases, whereby the components contained in the fluid to be processed in a dispersed phase are formed into microparticles having a desired diameter.

Abstract: The present invention relates to a process for manufacturing microcrystalline ezetimibe containing granulate, wherein a) ezetimibe is dissolved; b) the dissolved ezetimibe is precipitated with water, which if necessary contains pharmaceutical excipients, preferably lauryl-sulfate derivatives, and c) granulates are formed from the obtained suspension by spraying the suspension onto pharmaceutical excipients. A further aspect of the present invention is the granulate obtained by the present process and the pharmaceutical composition containing such granulate.

Abstract: The disclosure provides granular forms of porous biomaterials and methods for forming and applying these biomaterials, including uses to promote vascularization and tissue ingrowth.

Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

Abstract: The invention provides compositions and methods to treat microbial infections in animals, to inhibit the replication of microbes in infected cells, and to kill pathogens in infected cells. The methods can include administering to an animal in need of such treatment an effective antimicrobial amount of a composition comprising polyanhydride microparticles or nanoparticles that encapsulate a plurality of antimicrobial agents. The polyanhydride microparticles or nanoparticles can be, for example, copolymers of sebacic anhydride (SA) and 1,6-bis-(p-carboxyphenoxy)hexane (CPH) anhydride, copolymers of 1,8-bis(carboxyphenoxy)-3,6-dioxaoctane (CPTEG) anhydrides and 1,6-bis-(p-carboxyphenoxy)hexane (CPH) anhydride, or various combinations thereof.

Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.

Abstract: A shampoo composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair during the cleansing process. The shampoo composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier.

Abstract: This disclosure features human milk permeates and compositions containing the same obtained from fractionated whole human milk. The oligosaccharide rich permeate and permeate compositions of the present invention are useful as nutritional supplements for pre-term and full term infants, for establishing or maintaining gut flora and for treating the symptoms of inflammatory bowel disease.

Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.

Abstract: Disclosure is provided for methods of preventing, removing or inhibiting microbial biofilm formation or microbial infection in a plant or plant part thereof, including applying thereto a treatment effective amount of an active compound as described herein, or an agriculturally acceptable salt thereof. Methods of enhancing a microbicide (e.g., including a copper, antibiotic, bacteriophage, etc.) and/or plant defense activator are also provided, including applying an active compound as described herein. Compositions comprising an active compound as described herein in an agriculturally acceptable carrier are also provided, and in some embodiments the compositions further include a microbicide (e.g., including copper, antibiotic, bacteriophage, etc.) and/or plant defense activator.

Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.

Abstract: The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body. The methods of the present invention comprise use of anti-glycation composition for the treatment and prevention of glycation related conditions including diabetes, atherosclerosis, arthritis, mental conditions and vision impairment.

Abstract: In one aspect, the invention relates to methods for treating a disease or condition associated with abnormal glucose metabolism. In another aspect, the invention relates to a method for reducing incidence or progression of insulin-dependent diabetes mellitus. The methods include orally administering to a mammal in need thereof an effective amount of a composition, which includes a naturally occurring material derived from eggshell, eggshell membrane, or a combination thereof.

Abstract: A neutral-fat-level-regulating agent, a cholesterol-level-regulating agent, a free-fatty-acid-level-regulating agent or an anti-obesity agent, including: at least one of protopanaxatriol, panaxatriol, protopanaxadiol and panaxadiol which are aglycons of dammarane-type saponins and a hyperlipemia-ameliorating agent including: at least one of the neutral-fat-level-regulating agent, the cholesterol-level-regulating agent, the free-fatty-acid-level-regulating agent and the anti-obesity agent.

Abstract: Materials with high levels of unsaponifiable matter, such as extracts from plants, produce hydrolysates with unique properties. The application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6 weight percent of the material), produces a product with properties significantly different from those products resulting from the conventional saponification of materials with less than 6 weight percent of unsaponifiables. The hydrolysates of the present invention are substantive, resisting both physical and aqueous-based removal from skin and hair, exhibit a unique surfactant property, and are not foaming agents with water. Hydrolysates according to the present invention may be used to enhance the performance of cosmetics and pharmaceuticals.

Abstract: One or more embodiments of the invention are directed to methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans. The methods comprise the step of administering to the patients a composition comprising a therapeutically effective amount of an extract from pomegranate.

Abstract: A process of enzymatic degumming edible oils, comprising treating edible oil with a lipid acyltransferase so as to transfer an acyl group from a major part of the phospholipid to one or more acyl acceptors, wherein the acyl acceptor may be any compound comprising a hydroxyl group. In one embodiment preferably the acyl acceptor is water and in another embodiment preferably the acyl acceptor is one or more sterols and/or stanols. When the acyl acceptor is a stanol and/or sterol, one or more sterol esters and/or stanol esters are produced.

Abstract: A beverage cartridge includes a bottom wall and at least one sidewall forming a chamber in which a beverage can be prepared from a stored beverage product. The sidewall includes one or more pre-formed openings or openable portions. Openable portions may be scored lines or reduced-thickness lines or regions, which open to form exit paths for a prepared beverage when a compressive force is applied to the sidewall, such as by moving a portion of the bottom wall toward an upper end portion of the cartridge to deform the sidewall and open the openable portions. Where the sidewall instead includes pre-formed openings, these may be initially covered or sealed and provide existing exit paths for prepared beverage upon removal of the cover. Optionally, a filter element is provided inside the cartridge for retaining a used beverage product inside the cartridge as a prepared beverage exits from the cartridge.

Abstract: The present invention relates to preparations comprising (arabino)xylan oligosaccharides with average degree of polymerisation between 4 and 10 and average degree of arabinose substitution between 0.15 and 0.35, which beneficially modulate the intestinal flora, such preparation comprising both xylo- and arabinoxylo-oligosaccharides. Preferably, the arabinoxylooligosaccharides are substituted in part by hydroxycinnamic acids and exert antioxidant effects. Furthermore, it is preferred that the preparations according to the present invention have a nitrogen content below 0.16% (w/w) in order to ensure good organoleptic and color properties, particularly upon heating said preparations. In addition, food, beverage and nutritional supplement products comprising the preparations are provided as well as methods to prepare the said preparations.

Abstract: Provided is a method for manufacturing refined fats and oils. Here fats and oils are brought into contact with an adsorbent and subsequently treated with water vapor under at least one condition of the following conditions. In condition I, the time for which the fats and oils are brought into contact with the water vapor in a temperature range of 175° C. to 205° C. for from 5 to 110 minutes. In condition 2, the fats and oils are brought into contact with the water vapor in a temperature range of 205° C. to 215° C. for from 5 to 50 minutes. In condition 3, the fats and oils are brought into contact with the water vapor in a temperature range of 215° C. to 230° C. for from 5 to 30 minutes.

Abstract: An extraction device (110) for extracting at least one ingredient from a biological sample (112) is disclosed, specifically for extracting metabolites from a plant specimen. The extraction device (110) has at least one liquid charger (116) which is adapted to be brought in contact with a first side (122) of the sample (112). The liquid charger (116) is adapted to apply an extraction liquid (128), specifically at least one solvent, to the first side (122) of the sample (112). The extraction device (110) further has at least one sampling device (118) which is adapted to be brought in contact with a second side (124) of the sample (112). The sampling device (118) is adapted to collect sample fluid (126) comprising the extraction liquid (128) and the ingredient.

Abstract: This invention relates to a brew group for an infusion machine, in particular a machine for espresso coffee, having infusion means (43, 43b) designed for the preparation of infusions, a holding chamber (41) hydraulically connected to the said infusion means (43, 43b) and having at least two liquid inlets (411) allowing the delivery of liquids and heating means (46) capable of directly heating the liquids delivered to the holding chamber (41) through the inlets such as to hydraulically feed the infusion means (43, 43b) for the preparation of infusions. The invention also relates to a machine which includes the brew group and a method for operating the machine.

Abstract: The present invention corresponds to a method for the removal of unwanted toxic phenolic compounds such as a pesticide from foodstuffs, more particularly beverages. The method comprising contacting a selected polymer with the foodstuff. In a particular embodiment, the polymers are selected among polyaniline (PANI), polyaniline emeraldine base (PANI-EB) and polyaniline emeraldine salt (PANI-ES) polymers, or the polymers are selected among polyamidoamine (PAMAM) dendrimers functionalized with polyaniline (PANI), polyaniline emeraldine base (PANI-EB) and polyaniline emeraldine salt (PANI-ES) polymers.

Abstract: Disclosed herein are stabilized powder and aqueous formulations comprising a substantially water insoluble lipophilic bioactive compound and a micelle-forming surfactant. In one embodiment, the formulation further comprises a water soluble reducing agent, and/or a water insoluble reducing agent, and/or a metal chelator, and/or a metal bisulfite reducing agent, or combinations thereof, wherein the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 6 months or at least 12 months; and methods for preparing these formulations.

Abstract: A bakery product comprises white chocolate in the form of one or more discrete pieces, wherein the white chocolate comprises an effective amount of fiber to reduce shape deformation and/or browning of the white chocolate during the production of the bakery product.

Abstract: Process for the preparation of a spreadable edible dispersion wherein a mixture of oil and solid structuring agent particles is subjected to stirring and an aqueous phase and/or solid phase is gradually added to the mixture until a dispersion of the desired oil content is obtained, wherein the solid structuring agent particles have a microporous structure of submicron size particles.